Restless Legs Syndrome Drug Market Will Exceed $1 Billion in 2015
Posted on: Monday, 30 October 2006, 09:00 CST
WALTHAM, Mass., Oct. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the restless legs syndrome drug market will exceed $1 billion in 2015 up from $200 million in 2005.
According to the new Pharmacor report entitled Restless Legs Syndrome, the market will be driven by increases in the diagnosed population and the launch of three new drugs from Schwarz, XenoPort, and Serono. Each of the three new agents will launch successfully for restless legs syndrome on the strength of product differentiation: Schwarz's rotigotine CDS (Neupro) will boast a transdermal formulation; XenoPort's XP-13512 will possess improved pharmacokinetics; and Serono's safinamide will offer new mechanisms of action.
"The approval of Schwarz's rotigotine CDS, and XenoPort's XP-13512 will drive a four-fold increase in the drug-treated population and a six-fold increase in total market sales by 2015," said Julie Kerner, Ph.D., analyst at Decision Resources. "The most successful emerging agent in the restless legs syndrome market will be rotigotine CDS, sales for which will account for 46% of the total restless legs syndrome market growth by 2015."
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease
- Neupro(R) Filed With the FDA for the Treatment of Restless Legs Syndrome
- Neupro(R) Filed in Europe for the Treatment of Restless Legs Syndrome
- Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients With Restless Legs Syndrome
- Boehringer Ingelheim Launches National Educational Initiative to Improve Awareness and Understanding of Restless Legs Syndrome (RLS)
- Recent Epidemiology and Genetic Linkage Studies Confirm the Fact That Restless Legs Syndrome (RLS) is a Distinct Disease Caused By Genetic and Neurosensory Defects Rather Than Psychological Ones
- Large Clinical Study Results Show Pramipexole Rapidly Relieves Restless Legs Syndrome Symptoms and Improves Sleep
- Research and Markets: Restless Legs Syndrome - Recognition Lacking Still
- Diagnosing Restless Legs Syndrome (RLS) in Primary Care
 |
 |
User Comments (0)
RSS Feeds